Graduate Program in Translational Biology and Molecular Medicine

About Us

The interdepartmental Translational Biology and Molecular Medicine Graduate Program at Baylor College of Medicine is a new complementary approach to train individuals in translational biology and promote collaborations between clinical and basic science faculty.

The program aims to develop a new workforce with firsthand experience in translational research and leadership training to serve as catalysis to move discoveries effectively between bench and bedside.

TBMM is one of 23 programs around the country supported by the Howard Hughes Medical Institute Med Into Grad Initiative, which is designed to develop a cadre of Ph.D. researchers who have an understanding of medicine and pathobiology and are committed to working at the interface of the basic sciences and clinical medicine.

What is Translational Biology?

  • Experimental nonhuman and nonclinical studies conducted with the intent of developing principles for the discovery of new therapeutic strategies.
  • Clinical investigations that provide a biological foundation for the development of improved therapies
  • The definition of guidelines for drug development or for the identification and validation of clinically relevant biomarkers
  • Any clinical trial initiated in accordance with the above goals
  • Basic science studies that define the biological effects of disease pathogenesis and therapeutics in humans

Program Goals

  • Continue advances in basic and clinical science with individuals capable of integrating diverse areas.
  • Provide interdisciplinary training and leadership qualities that utilize the problem solving abilities of teams.
  • Ensure that bidirectional transfer of information between “bench” and “bedside” occurs.
  • Instill the power of current basic science and encourage the formulation of challenging questions based on bedside observations.
  • Educate on the cell and subcellular levels and familiarize researchers with integrated organ system function and disease processes.
  • Train researchers how to move the development a promising therapeutic intervention beyond Phase I testing.